

You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for TDP-43
Antibody Characterization Report for TDP-43
Head-to-head comparison of available commercial antibodies against TDP-43 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.131852.2. The following study was funded in part by Genome Québec's Genomics Integration Program, awarded to the research laboratory of Peter S. McPherson. This work was supported by the ALS-Reproducible Antibody Platform (ALS-RAP), a public-private partnership established by three prominent ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
Q13148, amyotrophic lateral sclerosis, TAR DNA-binding protein 43, antibody characterization, TDP-43, antibody validation, ALS-RAP, TARDBP
Q13148, amyotrophic lateral sclerosis, TAR DNA-binding protein 43, antibody characterization, TDP-43, antibody validation, ALS-RAP, TARDBP
Laflamme, C., et al., Opinion: Independent third-party entities as a model for validation of commercial antibodies. N Biotechnol, 2021. 65: p. 1-8 DOI: 10.1016/j.nbt.2021.07.001.
Laflamme, C., et al., Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72. Elife, 2019. 8 DOI: 10.7554/eLife.48363.
Wang, M., et al., Version 4.0 of PaxDb: Protein abundance data, integrated across model organisms, tissues, and cell-lines. Proteomics, 2015. 15(18): p. 3163-8 DOI: 10.1002/pmic.201400441.
Cell, 2020. 180(2): p. 387-402 e16 DOI: 10.1016/j.cell.2019.12.023.
DepMap, Broad. 2019.
2021 DOI: https://doi.org/10.5281/zenodo.5717510.
Ayoubi, R., et al., Antibody screening by Immunoprecitation. 2021 DOI: https://doi.org/10.5281/zenodo.5717516.
Alshafie, W., P. McPherson, and C. Laflamme, Antibody screening by Immunofluorescence. 2021 DOI: https://doi.org/10.5281/zenodo.5717498.
17 Research products, page 1 of 2
- 2022IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2022IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
- 2023IsAmongTopNSimilarDocuments
- 2021IsAmongTopNSimilarDocuments
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average visibility views 214 download downloads 172 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).1 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average Powered byBIP!
- 214views172downloads



Head-to-head comparison of available commercial antibodies against TDP-43 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.131852.2. The following study was funded in part by Genome Québec's Genomics Integration Program, awarded to the research laboratory of Peter S. McPherson. This work was supported by the ALS-Reproducible Antibody Platform (ALS-RAP), a public-private partnership established by three prominent ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.